Systemic sclerosis and myositis extractable nuclear antigen (ENA) analysis : profile of a cohort of subjects with isolated Raynaud&apos;s phenomenon by R. Gualtierotti et al.
[AB1013] SYSTEMIC SCLEROSIS AND MYOSITIS EXTRACTABLE NUCLEAR ANTIGEN 
(ENA) ANALYSIS: PROFILE OF A COHORT OF SUBJECTS WITH ISOLATED RAYNAUD'S 
PHENOMENON 
 
R. Gualtierotti1,2, F. Ingegnoli1,2, T. Schioppo1, C. Lubatti1, S. Zeni1, C. Mastaglio3, V. 
Galbiati3, C. Grossi4, M. O. Borghi4, L. Castelnovo5, P. L. Meroni1,2. 1Division of 
Rheumatology, Ist. Ortopedico G. Pini; 2Dept. of Clinical Sciences and Community 
Health, University of Milan, Milan; 3Department of Rheumatology, Ospedale Moriggia-
Pelascini, Gravedona; 4Experimental Laboratory of Immunological and Rheumatologic 
Researches, Istituto Auxologico Italiano, Milan; 5UOC Medicina Interna, Presidio 
Ospedaliero di Saronno, AO di Busto Arsizio, Busto Arsizio, Italy 
 
Background: Raynaud's phenomenon (RP) may predate an overt Connective Tissue Disease 
(CTD) of the “Scleroderma spectrum” such as Systemic sclerosis (SSc). The predictive role of 
auto-antibodies (auto-Abs) such as ANA for the development of a CTD in patients with isolated 
RP (i.e. with no other signs or symptoms of CTD) is well known, whereas data regarding the 
prevalence of anti-ENA in such patients are lacking. 
Objectives: Our aim was to evaluate the profile of anti-ENA in patients with isolated RP. 
Methods: Sera were analyzed for anti-ENA by EUROLINE “Scleroderma profile” (antigens: 
Scl70, CENP A, CENP B, RP11, RP155, fibrillarin (Fib), NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, 
PDGFR, Ro-52) and “Myosites profile” (antigens: Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-
7, PL-12, EJ, OJ, Ro-52) [EUROIMMUN AG Leuback, Germany]. 
Results: A total of 115 adults (105 females and 10 males) with isolated RP were enrolled in two 
Italian Rheumatology Centers (G. Pini Institute, Milan and Moriggia-Pelascini Hospital, 
Gravedona) from March 2011 to September 2013. Forty-four of 115 (38.0%) subjects were 
positive for at least one anti-ENA; 71 out of 110 (61.7%) were negative both for Scleroderma 
and Myosites profiles (see table 1 and 2). 
 
Conclusions: Up to 38% of RP subjects were positive for at least one anti-ENA. The detection 
of anti-ENA since the first Rheumatologic evaluation may aid the specialist in achieving an 
earlier diagnosis. 
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